Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageWe are a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients living with severe autoimmune diseases. Our lead clinical-stage candidate, claseprubart, is a monoclonal antibody that is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein (“C1s”) – enabling less frequent and more convenient self-administered subcutaneous (“S.C.”) injections suitable for a pre-filled pen.
In the company’s own words · 10-K filed Mar 9, 2026 · SEC EDGAR
Business segments
Q3 2024 · $4.4MThe company’s own SEC segment disclosure.
- License$2.2M50%
- License$2.2M50%
For the full year FY2025, revenue was $2.0M (−67% year on year) and net income −$162M. Its largest product in 2024-Q3 was License at $2.2M, 50.3% of the disclosed total, just ahead of License at 49.7%.
Raw charts
8 series · TTMAs reported to the SEC, without any scoring.